Akeso (HKSE:09926) Dividend Payout Ratio : 0.00 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Akeso Dividend Payout Ratio?

Akeso's dividend payout ratio for the months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for Akeso's Dividend Payout Ratio or its related term are showing as below:

HKSE:09926's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.44
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-06-03), the Dividend Yield % of Akeso is 0.00%.

Akeso's Dividends per Share for the months ended in Dec. 2023 was HK$0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Akeso Dividend Payout Ratio Historical Data

The historical data trend for Akeso's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akeso Dividend Payout Ratio Chart

Akeso Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividend Payout Ratio

Get a 7-Day Free Trial

Akeso Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Dividend Payout Ratio	Get a 7-Day Free Trial						-	-	-	-	-

Competitive Comparison of Akeso's Dividend Payout Ratio

For the Biotechnology subindustry, Akeso's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akeso's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akeso's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Akeso's Dividend Payout Ratio falls into.

Akeso Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Akeso's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2023 )	/	EPS without NRI (A: Dec. 2023 )
	=	0	/	2.579
	=	0.00

Akeso's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	-0.648
	=	N/A

Akeso (HKSE:09926) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Akeso Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Akeso's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Akeso (HKSE:09926) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akeso Inc (HKSE:09926) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

AKESF:USA 4RY:Germany

Address

6 Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437

Website

https://www.akesobio.com

Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China.

Executives

Xia Yu	2501 Other
Wang Zhongmin Maxwell	2501 Other
Li Baiyong	2501 Other
Green Court Capital Holdings Limited	2201 Interest of corporation controlled by you
Green Court Capital Management Limited	2102 Investment manager
Green Court Management Holdings Llc	2201 Interest of corporation controlled by you
Yao Yulin	2201 Interest of corporation controlled by you
Shenzhen Capital Group Co., Ltd.	2201 Interest of corporation controlled by you
Xia Yu	2501 Other
Shen Zhen Shi Chuang Xin Tou Zi Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Zheng Xun
Zhong Shan Shi Xun Xiang Gu Quan Tou Zi Guan Li Qi Ye You Xian He Huo
Cantrust (far East) Limited	2301 Trustee
Aquae Hyperion Limited	2101 Beneficial owner
Htkf Investments Limited	2101 Beneficial owner

Akeso (HKSE:09926) Headlines

No Headlines